StageAcquired | Acquired
About Genvault Corporation
GENVAULT CORPORATION, based in Carlsbad, California, is a provider of biosample workflow, transport, and storage solutions for genomic medicine, discovery and identification. The company's dry state platform aims to allow the extraction, preservation, recovery, and distribution of DNA at room temperature. The company's system will also accommodate proteins and RNA.
Missing: Genvault Corporation's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Genvault Corporation's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Genvault Corporation
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Genvault Corporation is included in 1 Expert Collection, including Omics.
Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data
Genvault Corporation Patents
Genvault Corporation has filed 5 patents.
Molecular biology, Oceanographical terminology, Biotechnology, Biomolecules, Oceanography
Molecular biology, Oceanographical terminology, Biotechnology, Biomolecules, Oceanography
Latest Genvault Corporation News
Jan 25, 2022
Founded by an Experienced Management Team and Built on the Reach and Infrastructure of the San Diego Blood Bank January 25, 2022 09:00 AM Eastern Standard Time SAN DIEGO--( BUSINESS WIRE )--Excellos, Incorporated, a cell therapy Contract Development and Manufacturing Organization (CDMO), announces its official corporate launch and closing of $15M in growth funding from Telegraph Hill Partners (THP). Built on the foundation of the San Diego Blood Bank (SDBB), Excellos is focused on supplying cGMP cellular products and services, together with process development and manufacturing expertise to scientists and clinicians working with cell and gene therapies. The company’s collection network consists of nine SDBB centers in the San Diego area that see an average of over 70,000 diverse donors annually, as well as exclusive access to select, consented material from SDBB’s public cord blood bank. Excellos also has access to a nationwide collection network giving it one of the largest cellular material procurement portfolios. Uniquely connecting its broad collection network to state-of-the-art cGMP and R&D facilities in San Diego, Excellos provides a full suite of innovative end-to-end capabilities to facilitate the development and manufacture of autologous and allogeneic cell therapies. Excellos’ experience includes working with therapeutic companies developing chimeric antibody receptor-engineered T cells (CAR-T), tumor-infiltrating lymphocytes (TILs), and providing isolated immune cells that are integral to the advancement of immunotherapies. “Excellos will create highly characterized, standardized cell products and custom services that are essential for advanced therapeutics,” said David Wellis Ph.D., CEO of Excellos. “The SDBB had been incubating Excellos for a number of years, but fully capitalizing on the rapidly growing opportunity required significantly more resources than the SDBB was able to provide. We will now be able to focus exclusively on the needs of the expanding cell and gene therapy industry through the development of our data-driven platform to enable the characterization of cellular therapeutics starting at the donor level. The funding from THP will allow a significant facility expansion and overall growth in the capabilities of our organization.” “The growth in the cell and gene therapy industry is driving a surge in demand for critical human cells, tissues, and services to support the development and commercialization of new products,” said Paul Grossman, Ph.D., J.D., Partner at THP. “We look forward to partnering with Excellos and their proven leadership team. Their exclusive access to one of the industry’s largest donor bases, coupled with their technology-focused research and development activities, will help to accelerate the advancement of cell and gene therapies for those patients in need.” Paul Grossman, Alex Herzick, and Deval Lashkari from THP have joined the Excellos Board concurrent with the financing. Excellos’ founding leadership team brings a wealth of commercial and industry experience to bear. Chief Executive Officer David Wellis Ph.D., previously served as CEO of SDBB for nine years where he foresaw the need for products and services to serve the then nascent cell and gene therapy industry. His guidance allowed the organization to meet these needs, a path that ultimately led to the formation of Excellos. David has also held senior leadership roles at both Illumina and GenVault Corporation. Chief Commercial Officer George Eastwood, brings significant experience in the cell and gene therapy space, with a focus on cGMP materials and cell manufacturing. He served as VP, Global Sales and Business Development for HemaCare, and in his over five years there, he saw the company through a period of dramatic expansion that culminated in its acquisition by Charles River in 2020. Chief Scientific Officer Rob Tressler Ph.D., brings vast experience in R&D for advanced cell-based therapies. Most recently, as CSO of SDBB, he led the cell therapy, immunohematology, components manufacturing, and cord blood banking labs. Rob also has extensive drug development experience, both as Head of Preclinical Oncology at Geron Inc. and VP of R&D at Cellerant Therapeutics. About Excellos: Built on the foundation of the San Diego Blood Bank, Excellos is focused on supplying cGMP cellular products and services, together with process development and manufacturing expertise to scientists and clinicians working with cell and gene therapies. Excellos is dedicated to improving human life by providing critical products and services to life science research and the next generation of cell and gene therapies. Learn more at www.excellos.com About Telegraph Hill Partners: Telegraph Hill Partners, founded in 2001 and based in San Francisco, CA, invests in commercial stage life science, medical technology, and healthcare companies. For more information, please see www.telegraphhillpartners.com Contacts
Genvault Corporation Frequently Asked Questions (FAQ)
When was Genvault Corporation founded?
Genvault Corporation was founded in 2001.
Where is Genvault Corporation's headquarters?
Genvault Corporation's headquarters is located at 6190 Corte Del Cedro, Carlsbad.
What is Genvault Corporation's latest funding round?
Genvault Corporation's latest funding round is Acquired.
How much did Genvault Corporation raise?
Genvault Corporation raised a total of $42.5M.
Who are the investors of Genvault Corporation?
Investors of Genvault Corporation include IntegenX, Domain Associates, Cross Creek, QuestMark Partners and Greenspring Associates.
Who are Genvault Corporation's competitors?
Competitors of Genvault Corporation include Arecor, Thermal Gradient, Celsis International, DNA Software, Proteopure and 10 more.
Compare Genvault Corporation to Competitors
EpigenDx is a genomic and epigenomic research company engaged in disease biomarker discovery and molecular diagnosis. The company aims to provide products related to DNA methylation analysis research. Currently available products include DNA methylation controls and validated DNA methylation assays for human, mouse, and rat. The company also aims to provide products and laboratory services for scientific researchers from academic, government and industrial communities. The company's commitment to quality comes from the company's desire and dedication to provide products and services to the company's customers. As a Biotage AB Certified Laboratory Service provider, EpigenDx has knowledge and expertise in Pyrosequencing and its many applications. CpG methylation and allele quantification analysis are conducted using Biotage's PSQ MD system, while short-read sequence analysis is carried out using Biotage's PSQ ID system.
SeiraD is engaged in research and development creating instrumentation for scientific problems. Their current focus is the DNA sequencing instrument.
EMD Biosciences, Novagen Brand, manufactures and sells molecular biology tools--including gene splicers, protein purifiers, and more--that boost important research and development involving DNA, genes, proteins and other building blocks of life.
Proteomics is widely viewed as the cornerstone of future success in drug discovery and clinical diagnostics, but the complexity of protein molecules and their interactions requires new tools to find and understand biomarkers and protein functions. A critical step in the research process is to properly prepare the molecular sample before analysis can begin. Proteopure, Inc.'s technology is the foundation of a simple laboratory "kit" that fills unmet research needs.nProteopure developed and is now marketing sample protein preparation kits. In addition, Proteopure markets complementary products where there is overlapping customer synergy. These other products include a kit for membrane sample preparation, a kit for measuring protein concentration, fluorescent nanoclusters and beads for labeling proteins, and fluorescent tagged genes for measuring protein expression and location.
VivoPath is a preclinical screening company, offering the company's clients discovery and development services for in vivo testing. VivoPath aims to provide integrated in vivo studies led by established experts in drug development. Efficacy is established for animal models in the areas of metabolic disease, inflammation, neurodegenerative disease, and infectious diseases. Formulation screening is carried out to select the most appropriate delivery system for administration. Pharmacokinetic evaluation is carried out to assess exposure and bioavailability. Tolerability is assessed with evaluations of clinical signs, clinical chemistry and hematology. The resulting program aims to deliver the client an in vivo therapeutic index (TI) report on which to assess candidates for subsequent development. VivoPath can also help clients at any individual step in this preclinical screening process. VivoPath's commitment is to provide scientific expertise in in vivo drug discovery in order to increase productivity from research into drug development.
Sword Diagnostics is a life sciences company created in response to the needs of the research, pharmaceutical, and clinical communities. Although researchers are discovering thousands of biomarkers associated with both healthy and diseased-related biological processes, today's life science tools are unable to effectively measure, quantify, and determine the ultimate value of these biological markers. Sword Diagnostics' technology is directly aimed at making it easier to understand these newly emerging biomarkers, as well as extending the utility of existing diagnostics assays. Sword's mission is to provide the next-generation detection technology to life scientists, enabling them to continue advances in medical research, drug discovery and the provision of health care products and services.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.